Francis David Segal
Known title: DirectorCIK: 0002066872
Associated companies
Transaction History
| NGVT | ▲ Buy | Grant | 335 | $24K | 10/1/2026 | View on chart |
| NGVT | ▲ Buy | Grant | 328 | $24K | 7/1/2026 | View on chart |
| NGVT | ▲ Buy | Grant | 1,904 | $0 | 4/30/2026 | View on chart |
| NGVT | ▲ Buy | Grant | 329 | $24K | 4/1/2026 | View on chart |
| NGVT | ▲ Buy | Grant | 396 | $24K | 1/2/2026 | View on chart |
| NGVT | ▲ Buy | Grant | 414 | $23K | 10/1/2025 | View on chart |
| NGVT | ▲ Buy | Grant | 507 | $23K | 7/1/2025 | View on chart |
| NGVT | ▲ Buy | Grant | 677 | $23K | 5/1/2025 | View on chart |
| NGVT | ▲ Buy | Grant | 4,057 | $0 | 5/1/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Ingevity sets Q3 2026 earnings date; article discusses holding reasons
Ingevity announced the dates for its third‑quarter 2026 earnings release and the accompanying webcast. A recent Yahoo article outlined several points that investors have cited for maintaining their positions in the company. The upcoming earnings call may provide additional data that could influence market views.
Ingevity sets Q3 2026 earnings date; article discusses holding reasons. Ingevity announced the dates for its third‑quarter 2026 earnings release and the accompanying webcast. A recent Yahoo article outlined several points that investors have cited for maintaining their positions in the company. The upcoming earnings call may provide additional data that could influence market views.